Top

Published in:

01-02-2006 | UPDATE

Staging and follow-up of gastrointestinal tumors with PET/CT

Authors: S. J. Rosenbaum, H. Stergar, G. Antoch, P. Veit, A. Bockisch, H. Kühl

Published in: Abdominal Radiology | Issue 1/2006

Abstract

Positron emission tomography (PET) is a functional imaging modality that has been documented to be useful in patient care. Oncologic PET imaging is used for a wide variety of neoplasms, mainly for staging and follow-up, differentiation of equivocal morphologic findings, therapy stratification, and monitoring. Because PET imaging is based on the physiologically mediated distribution of the administered tracer but not on anatomic information, the addition of computed tomography (CT) to PET may improve the interpretation of PET. Combined PET and CT offers several potential advantages over PET alone that may influence the clinical routine. PET/CT was introduced into clinical use only 3 years ago and has found widespread application within only 1 to 2 years. This article summarizes preliminary data of clinical applications for PET/CT in gastrointestinal tumors.

Adams S, Baum R, Rink T, et al. (1998) Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 25:79–83PubMed

Anderson CD, Rice MH, Pinson CW, et al. (2004) Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg 8:90–97PubMed

Antoch G, Kanja J, Bauer S, et al. (2004) Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 45:357–365PubMed

Antoch G, Saoudi N, Kuehl H, et al. (2004) Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 1(22):4357–4368

Avril N (2004) GLUT1 expression in tissue and 18F-FDG uptake. J Nucl Med 45:930–932PubMed

Bastiaannet E, Groen H, Jager PL, et al. (2004) The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev 30:83–101PubMedCrossRef

Beyer T, Antoch G, Blodgett T, et al. (2003) Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging 30:588–596PubMedCrossRef

Beyer T, Townsend DW, Brun T, et al. (2000) A combined PET/CT scanner for clinical oncology. J Nucl Med 41:1369–1379PubMed

Block MI, Sundaresan SR, Patterson GA (1997) Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg 64:770–777PubMedCrossRef

10.

Bohm B, Voth M, Geoghegan J, et al. (2004) Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors. J Cancer Res Clin Oncol 130:266–272PubMed

11.

Burger I, Goerres GW, Schulthess GK, et al. (2002) PET/CT: diagnostic improvement in recurrent colorectal carcinoma compared to PET alone. Radiology 225(suppl P):242

12.

Charron M, Beyer T, Bohnen NN, et al. (2000) Image analysis in patients with cancer studied with a combined PET and CT scanner. Clin Nucl Med 25:905–910PubMed

13.

Chen YK, Kao CH, Liao AC, et al. (2003) Colorectal cancer screening in asymptomatic adults: the role of FDG PET scan. Anticancer Res 23(5b):4357–4361PubMed

14.

Cohade C, Osman M, Leal J, Wahl R (2003) Direct comparison of 18F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med 44:1797–1803PubMed

15.

Delbeke D, Rose DM, Chapman WC, et al. (1999) Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med 40:1784–1791PubMed

16.

De Potter T, Flamen P, Van Cutsem E, et al. (2002) Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med Mol Imaging 29:525–529PubMed

17.

Diederichs CG, Staib L, Vogel J, et al. (2000) Values and limitations of 18F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses. Pancreas 20:109–116PubMed

18.

Even-Sapir E, Parag Y, Lerman H, et al. (2004) Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology 232:815–822PubMed

19.

Flamen P, Lerut A, Van Cutsem E (2000) Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 18:3202–3210PubMed

20.

Flanagan FL, Dehdashti F, Siegel BA (1997) Staging of esophageal cancer with FDG-PET. AJR 168:417–424PubMed

21.

Franke J, Rosenzweig S, Reinartz P, et al. (2000) Value of positron emission tomography (18F-FDG-PET) in the diagnosis of recurrent rectal cancer. Chirurg 71:80–85PubMed

22.

Freudenberg LS, Antoch G, Beyer T, et al. (2003) Diagnosis of labia metastasis by F-18 FDG PET and CT fusion imaging in sarcoma follow-up. Clin Nucl Med 28:636–637PubMedCrossRef

23.

Fritscher-Ravens A, Bohuslavizki KH, Broering DC, et al. (2001) FDG PET in the diagnosis of hilar cholangiocarcinoma. Nucl Med Commun 22:1277–1285PubMedCrossRef

24.

Gayed I, Vu T, Iyer R, et al. (2004) The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 45:17–21PubMed

25.

Himeno S, Yasuda S, Shimada H (2002) Evaluation of esophageal cancer by positron emission tomography. Jpn J Clin Oncol 32:340–346PubMedCrossRef

26.

Ho CL, Yu SC, Yeung DW (2003) 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 44:213–221PubMed

27.

Hoffmann M, Kletter K, Diemling M, et al. (1999) Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol 10:1185–1189PubMedCrossRef

28.

Hofmann M, Maecke H, Borner R, et al. (2001) Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 28:1751–1757PubMed

29.

Huebner RH, Park JE, Shepard JE, et al. (2000) A meta-analysis of the literature for whole body FDG-PET detection of recurrent colorectal cancer. J Nucl Med 41:1177–1189PubMed

30.

Jadvar H, Fischman AJ (2001) Evaluation of pancreatic carcinoma with FDG PET. Abdom Imaging 26:254–259PubMedCrossRef

31.

Jones DR, Parker LA Jr, Detterbeck FC (1999) Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. Cancer 85:1026–1032PubMed

32.

Kamel EM, Thumsirn M, Truninger K, et al. (2004) FDG Accumulations in the gastrointestinal tract in PET/CT: correlation with endoscopic and histopathologic results. J Nucl Med 45:1804–1810PubMed

33.

Kato H, Miyazaki T, Nakajima M, et al. (2004) Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma. Br J Surg 91:1004–1009PubMedCrossRef

34.

Kato H, Miyazaki T, Nakajima M, et al. (2005) The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer 1;103:148–156

35.

Keiding S, Hansen SB, Rasmussen HH, et al. (2000) Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Ugeskr Laeger 7;162:782–785

36.

Khan MA, Combs CS, Brunt EM, et al. (2000) Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 32:792–797PubMed

37.

Kim YJ, Yun M, Lee WJ, et al. (2003) Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging 30:1467–1472PubMed

38.

Kinkel K, Lu Y, Both M, et al. (2002) Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 224:748–756PubMed

39.

Kluge R, Schmidt F, Caca K, et al. (2001) Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology 33:1029–1035PubMedCrossRef

40.

Kole AC, Plukker JT, Nieweg OE (1998) Positron emission tomography for staging oesophageal and gastroesophageal malignancy. Br J Cancer 74:521–527

41.

Kowalski J, Henze M, Schuhmacher J, et al. (2003) Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 5:42–48PubMed

42.

Kuehle C, Veit P, Antoch G, et al. (2005) Contrast-enhanced dark lumen PET/CT and MR colonography in a rodent polyp model—initial results with histopathological correlation. AJR Am J Roentgenol 185:1045–1047PubMed

43.

Kumar R, Xiu Y, Potenta S, et al. (2004) 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas. J Nucl Med 45:1796–17803PubMed

44.

Lemke AJ, Niehues SM, Hosten N, et al. (2004) Retrospective digital image fusion of multidetector CT and 18F-FDG PET: clinical value in pancreatic lesions—a prospective study with 104 patients. J Nucl Med 45:1279–1286PubMed

45.

Luketich JD, Schauer P, Meltzer CC (1997) The role of positron emission tomography in staging esophageal cancer. Ann Thorac Surg 64:765–769PubMedCrossRef

46.

McAteer D, Wallis F, Couper G (1999) Evaluation of ¹⁸F-FDG positron emission tomography in gastric and oesophageal carcinoma. Br J Radiol 72:525–529PubMed

47.

Mertz HR, Sechopoulos P, Delbeke D, Leach SD (2000) EUS, PET, and CT scanning for evaluation of pancreatic adenocarcinoma. Gastrointest Endosc 52:367–371PubMedCrossRef

48.

Mochiki E, Kuwano H, Katoh H, et al. (2004) Evaluation of 18F-2- deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg 28:247–253PubMedCrossRef

49.

Nakamoto Y, Chin BB, Cohade C, et al. (2004) PET/CT: artifacts caused by bowel motion. Nucl Med Commun 25:221–225PubMed

50.

Ott K, Fink U, Becker K, et al. (2003) Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 15(21):4604–4610

51.

Ott K, Weber WA, Fink U, et al. (2003) Fluorodeoxyglucose-positron emission tomography in adenocarcinomas of the distal esophagus and cardia. World J Surg 27:1035–1039PubMedCrossRef

52.

Pereira PL, Clasen S, Boss A, et al. (2004) Radiofrequency ablation of liver metastases. Radiologe 44:347–357PubMedCrossRef

53.

Rankin SC, Taylor H, Cook GJR (1998) Computed tomography and positron emission tomography in the pre-operative staging of oesophageal carcinoma. Clin Radiol 53:659–665PubMed

54.

Reske SN, Kotzerke J (2001) FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, “Onko-PET III,” 21 July and 19 September 2000. Eur J Nucl Med 28:1707–1723PubMed

55.

Rodriguez M, Ahlstrom H, Sundin A, et al. (1997) [18F] FDG PET in gastric non-Hodgkin’s lymphoma. Acta Oncol 36:577–584PubMedCrossRef

56.

Rohren EM, Turkington TG, Coleman RE (2004) Clinical applications of PET in oncology. Radiology 2311:305–332

57.

Rosa F, Meimarakis G, Stahl A, et al. (2004) Colorectal cancer patients before resection of hepatic metastases. Impact of (18) F-FDG PET on detection of extrahepatic disease. Nuklearmedizin 43:135–140PubMed

58.

Schaefer NG, Hany TF, Taverna C, et al. (2004) Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging-do we need contrast-enhanced CT? Radiology 232:823–829PubMed

59.

Schlag PM, Amthauer H, Stroszcynski C, Felix R (2001) Einfluß der Positronenemissionstomographie auf die chirurgische Therapieplanung beim colorectalen Rezidivtumor. Chirurg 72:995–1002PubMed

60.

Sperti C, Pasquali C, Decet G, et al. (2005) F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective study. J Gastrointest Surg 9:22–29PubMedCrossRef

61.

Stahl A, Ott K, Weber WA, et al. (2003) FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 30:288–295PubMedCrossRef

62.

Sundin A, Eriksson B, Bergstrom M, et al. (2004) PET in the diagnosis of neuroendocrine tumors. Ann NY Acad Sci 1014:246–257PubMed

63.

Stroobants S, Goeminne J, Seegers M, et al. (2003) 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 39:2012–2020PubMedCrossRef

64.

Tatlidil R, Jadvar H, Bading JR, Conti PS (2002) Incidental colonic fluorodeoxyglucose uptake: correlation with colonoscopic and histopathologic findings. Radiology 224:783–787PubMed

65.

Truong MT, Erasmus JJ, Munden RF, et al. (2004) Focal FDG uptake in mediastinal brown fat mimicking malignancy: a potential pitfall resolved on PET/CT. AJR 183:1127–1132PubMed

66.

Tutt ANJ, Plunkett TA, Barrington SF, Leslie MD (2004) The reole of positron emission tomography in the management of colorectal cancer. Colorectal Dis 6:2–9PubMedCrossRef

67.

van den Abbeele AD, Badawi RD, Cliche JP (2002) Response to imatinib mesylate (Gleevec) therapy in patients with advanced gastrointestinal stromal tumors (GIST) is demonstrated by F-18-FDG-PET prior to anatomic imaging with CT [abstract]. Radiology 225(suppl):424

68.

van Oosterom AT, Judson I, Verweij J, et al. (2001) Safety and efficacy of imatinib (STI 571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358:1421–1423PubMed

69.

Watanabe N, Hayashi S, Kato H, et al. (2004) FDG-PET imaging in duodenal cancer. Ann Nucl Med 18:351–353PubMed

70.

Weber WA, Ott K, Becker K (2001) Prediction of response to preoperative chemotherapy in adenocarcinomas of esophagogastric junction by metabolic imaging. J Clin Oncol 19:3058–3065PubMed

71.

Yeung HW, Macapinlac H, Karpeh M, et al. (1998) Accuracy of FDG-PET in gastric cancer. Preliminary experience. Clin Positron Imaging 1:213–221PubMed

72.

Yeung HWD, Macapinlac HA, Mazumdar M (1999) FDG-PET in esophageal cancer: incremental value over computed tomography. Clin Positron Imaging 5:255–260

73.

Yoshioka T, Yamaguchi K, Kubota K, et al. (2003) Evaluation of 18F-FDG PET in patients with a, metastatic, or recurrent gastric cancer. J Nucl Med 44:690–699PubMed

74.

Lauren PA (1965) The two main histologic types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 64:31–49PubMed

Title: Staging and follow-up of gastrointestinal tumors with PET/CT
Authors: S. J. Rosenbaum
H. Stergar
G. Antoch
P. Veit
A. Bockisch
H. Kühl
Publication date: 01-02-2006
Publisher: Springer-Verlag
Published in: Abdominal Radiology / Issue 1/2006
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI: https://doi.org/10.1007/s00261-005-0031-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Staging and follow-up of gastrointestinal tumors with PET/CT

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2006

Torsion of an accessory spleen

Intraluminal duodenal diverticulum: MR findings

Primary sarcoma of an abdominal aortic aneurysm

Hepatic hyperplastic nodules showing stains by portal blood flow: hemodynamics revealed by CTAP and CTHA

Pancreatic schwannoma: CT findings

Low-attenuation oral GI contrast agents in abdominal-pelvic computed tomography

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page